Progyny (PGNY) Set to Announce Earnings on Wednesday

Progyny (NASDAQ:PGNY) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Progyny to announce earnings of $0.3130 per share and revenue of $340.76 million for the quarter. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. The firm had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. Progyny’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.19 EPS. On average, analysts expect Progyny to post $1.25 EPS for the current fiscal year and $1.42 EPS for the next fiscal year.

Progyny Stock Performance

Shares of PGNY opened at $29.19 on Monday. The company’s 50-day simple moving average is $26.88 and its 200-day simple moving average is $24.43. Progyny has a 1 year low of $16.10 and a 1 year high of $33.06. The stock has a market capitalization of $2.24 billion, a PE ratio of 31.73, a P/E/G ratio of 2.01 and a beta of 1.02.

Insider Transactions at Progyny

In other news, COO Melissa B. Cummings sold 1,879 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer owned 66,496 shares in the company, valued at approximately $1,861,888. This represents a 2.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 11,500 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the sale, the director directly owned 6,792 shares of the company’s stock, valued at approximately $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 17,282 shares of company stock valued at $475,790. Insiders own 9.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on PGNY. Canaccord Genuity Group set a $35.00 price target on shares of Progyny in a research report on Friday, August 7th. Citizens Jmp increased their price objective on Progyny from $31.00 to $33.00 and gave the company a “market outperform” rating in a research note on Tuesday, September 8th. BTIG Research lifted their target price on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday, July 24th. Wall Street Zen cut Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.36.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.